(July 24, 2019)
College of Pharmacy and HOPE Center investigator, Sandipan Bhattacharjee, MS, PhD, published a new study in Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI). The study, titled Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study, used real-world evidence to review how the risk of hospitalization and mortality differed by Alzheimer disease (AD) medication in real-world settings. The study included over 21,000 Medicare patients and found significant differences in survival and hospitalization rates for patients receiving donepezil compared to other AD treatments. Dr. Bhattacharjee’s research team includes UA College of Pharmacy co-authors Dan Malone, RPh, PhD, FAMCP, Jeannie Lee, PharmD, and Terri Warholak, PhD. Additional co-authors include Sid Patanwala, PharmD, MPH, Wei-Hsuan Lo-Ciganic, PhD, Shannon Knapp, PhD, and William Burke, MD.
Key Findings included:
- Type of Alzheimer's disease medication initiation had overall all-cause mortality differences
- Donepezil initiation had survival benefit compared with other Alzheimer's disease medications
- Hospitalization risk differed by type of Alzheimer's disease medication initiation in intention-to-treat analysis